J&J focus on biotech, innovation paying off

10/25/2004 | Newhouse News Service

Johnson & Johnson's decision more than five years ago to make a multibillion dollar investment in pharmaceutical research and development is beginning to pay dividends for the company that was foundering in the late 1990s with a failed line of drugs. Now J&J expects to submit six drugs to the FDA by the end of next year, thanks to a refocus of its business on biotechnology and innovation.

View Full Article in:

Newhouse News Service

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC